menu
    • menu
    [{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ JW Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ JW Therapeutics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ Galapagos"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"PMC-309","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ PharmAbcine","highestDevelopmentStatusID":"4","companyTruncated":"Thermo Fisher Scientific \/ PharmAbcine"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Thermo Fisher Scientific

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vorasidenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves NGS Diagnostic for Grade 2 IDH-Mutant Glioma Therapy

                            Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma in 12 year and above patients.

                            Product Name : Voranigo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 21, 2024

                            Lead Product(s) : Vorasidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Galapagos Partners with Thermo Fisher To Expand CAR-T Manufacturing Network in the U.S.

                            Details : Thermo Fisher will provide GMP manufacturing, BioServices, and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program, GLPG-5101, developed for Non-Hodgkin’s lymphoma treatment.

                            Product Name : GLPG5101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : GLPG5101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer and Thermo Fisher Collaborate To Enhance Access To Cancer Medicines

                            Details : The collaboration aims to develop sequencing-based companion diagnostics to identify patients who may benefit from Bayer’s precision cancer therapies, including Nubeqa for prostate cancer.

                            Product Name : Nubeqa

                            Product Type : HPAPI

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relmacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : JW Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China

                            Details : The Partnership will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics’ lead product relmacabtagene autoleucel (“relma-cel”).

                            Product Name : Relma-cel

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Relmacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : JW Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PMC-309

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Pharmabcine Execute an Agreement with Thermo Fisher for the Development and Manufacturing Of Pmc-309

                            Details : Under this agreement, PharmAbcine will take advantage of Thermo Fisher's Quick to Clinic™ integrated service offering, a program that accelerates drug development for IND submission for Phase I.

                            Product Name : PMC-309

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : PMC-309

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entrectinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Thermo Fisher Signs CDx Agreement with Chugai Pharma

                            Details : Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.

                            Product Name : Rozlytrek

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 07, 2020

                            Lead Product(s) : Entrectinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth